Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2022
Industry sponsorship bias in cost effectiveness analysis: registry based analysis
22 June 2022 - The Tufts Cost-Effectiveness Analysis Registry was used to identify all CEAs published in Medline between 1976 and ...
Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
Posted by Michael Wonder on 20 Jun 2022
EFPIA and Vaccines Europe are deeply disappointed about the decision taken by World Trade Organization at the Ministerial Conference to endorse a TRIPS waiver for COVID-19 vaccines
17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...
Posted by Michael Wonder on 20 Jun 2022
PHARMAC's latest breast cancer drug funding 'way short' - advocate
16 June 2022 - On Wednesday PHARMAC announced $190 million to fund cancer treatments and other medicines. ...
Posted by Michael Wonder on 19 Jun 2022
IP waiver for COVID vaccines is a threat to future innovation
20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...
Posted by Michael Wonder on 19 Jun 2022
EU HTA regulation: international preparatory meeting in Cologne
17 June 2022 - At the invitation of IQWiG, 41 envoys from European HTA organisations and two from the EU ...
Posted by Michael Wonder on 19 Jun 2022
Drug pricing debate in Washington is a headache for pharma
17 June 2022 - Last-ditch effort by Democrats to pass slimmed-down version of Build Back Better could include measures on drug ...
Posted by Michael Wonder on 19 Jun 2022
Current issues in health technology assessment of cancer therapies: a survey of stakeholders and opinion leaders in Australia
17 June 2022 - The aim of this study was to find ways of bridging the gap in opinions concerning health ...
Posted by Michael Wonder on 19 Jun 2022
Klobuchar, Porter call for FTC to investigate price hikes by Janssen, Bristol Myers Squibb
14 June 2022 - Two prominent Democratic lawmakers are requesting that the Federal Trade Commission investigate whether price hikes for ...
Posted by Michael Wonder on 19 Jun 2022
Canadian regulator OKs Hugel's botulinum toxin product
16 June 2022 - Hugel said Thursday that it has obtained product approval from Health Canada for its botulinum toxin ...
Posted by Michael Wonder on 19 Jun 2022
Canadian drug prices: new regulations could save billions of dollars
15 June 2022 - New drug price regulations set to come into effect next month could lower spending on patented ...
Posted by Michael Wonder on 19 Jun 2022
Start of rolling review for adapted Spikevax COVID-19 vaccine
17 June 2022 - EMA has started a rolling review for a version of Spikevax adapted to provide better protection ...
Posted by Michael Wonder on 18 Jun 2022
Moderna receives FDA authorisation for emergency use of its COVID-19 vaccine for children 6 months of age and older
17 June 2022 - mRNA-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, ...
Posted by Michael Wonder on 18 Jun 2022
Pfizer-BioNTech COVID-19 vaccine receives FDA emergency use authorisation for children 6 months through 4 years of age
17 June 2022 - In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 vaccine elicited a strong immune response in this ...
Posted by Michael Wonder on 17 Jun 2022
Sierra Oncology announces submission of new drug application for momelotinib to US Food & Drug Administration
17 June 2022 - Submission seeks approval of momelotinib for the treatment of myelofibrosis. ...
Posted by Michael Wonder on 17 Jun 2022
NICE recommends new targeted treatment for early breast cancer
16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...